Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort

NCT ID: NCT07336836

Last Updated: 2026-01-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-02-23
• Study Completion Date: 2022-06-04

Brief Summary

The goal of this 5 day interventional study was to investigate the effects on multiple biological molecules (multi-omics) of Bryleos's commercially available oral LathMized™ Nicotinamide adenine dinucleotide (LNAD+) supplement in healthy adults aged 45-75 years. The main question to be answered was whether LNAD+ supplementation is associated with change in biological markers relevant to subjects' health. Also, the study determined whether this oral NAD+ formulation raised NAD+ levels including inside blood cells, after the 5 day treatment period, measured on post-treatment Day 1 (Day 6). Thus, the study compared NAD+ levels and impact on biological markers in the LNAD+ arm versus control placebo arm. Safety in this population was assessed using clinical laboratory tests, daily self-reporting of symptoms, and data from a wearable device.

Detailed Description

The RENEWAL-NAD+ study was designed as a single-center (distributed) Phase 0/1 double-blind, randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, and pharmacodynamic effects of five days of oral LNAD+ (LathMized™ NAD+) in healthy aging adults aged 45 to 75 years (inclusive).

The Renewal-NAD+ study was motivated by the dearth of evidence on oral NAD+ bioavailability and current limited understanding of the mechanisms of action and multi-omic footprint of NAD metabolism interventions from a systems biology standpoint. The present first-in-humans study was designed as a key translational step in establishing the safety, tolerability, and biological effects of LNAD+ in human subjects. The study aimed to demonstrate that theoretical advantages and documented preclinical benefits of enhanced NAD+ delivery translate to meaningful biological changes in healthy aging humans. It also provides meaningful data on the broader biological implications of NAD repletion that could translate into improvements in a multitude of therapeutic areas.

The novel formulation of NAD+ (LNAD+) had been commercially available prior to study initiation and was developed as a systematic formulation approach to the multifaceted barriers that have prevented effective oral NAD+ delivery. The proprietary LathMize™ Technology stabilizes and protects NAD+ before and during GI transit while facilitating absorption through multiple complementary mechanisms including optimizing particle size distribution to enable uptake through multiple pathways.

The study examined the effects of oral LNAD+ supplementation on intracellular and circulating NAD+ levels, as well as on levels of peripheral blood biomarkers, vitals, patient-reported outcomes, activity and sleep measures obtained via a wearable fitness device, and frequency of adverse events in a cohort of healthy adults The study aimed to enroll 60 adults in overall good health to obtain four longitudinal blood draws (two baseline and two on-treatment, respectively) and examined changes in circulating and intracellular NAD+, clinical laboratory tests, and plasma proteome and metabolome composition, in the LNAD+ arm relative to placebo.

The study was designed as a one-center but distributed trial that relied on the combination of ISB BioAnalytica's proprietary Electronic Data Capture (EDC) platform, at-home supplementation by the study participants, and mobile phlebotomy visits for venipuncture and vitals collection.

The study protocol was divided into 3 sequential phases:

Phase I: Screening/Eligibility. Phase II: Treatment Allocation and Wash-out. Phase III: Masked Treatment.

The study enrolled adults age 45-75 without pre-specified targeted health conditions with the following objectives:

1. The primary objective was to demonstrate the bioavailability of orally administered LNAD+ through measurement of both intracellular and extracellular NAD+ concentrations. This dual assessment approach recognizes that systemic NAD+ levels may not accurately reflect cellular delivery. Specifically, the selection of intracellular measurements in peripheral blood mononuclear cells provides direct evidence of cellular NAD+ augmentation rather than systemic exposure. The temporal assessment strategy captures both short-term responses and steady-state achievement, enabling characterization of pharmacokinetic and pharmacodynamic profiles.

2. Complementing this primary objective, the secondary objectives encompass comprehensive short-term safety evaluation and mechanistic characterization of LNAD+ through targeted biomarker assessment. The safety evaluation included analysis of adverse events, daily reports of physiological symptoms by body system, and detailed laboratory assessment of hepatic, renal, and hematological parameters, recognizing that metabolic interventions may have subtle systemic effects, as well as data obtained from a wearable device. The pharmacodynamic biomarker panel spanned multiple biological systems identified as responsive to NAD+ in preclinical studies, including inflammatory markers, metabolic parameters (lipid profiles, glucose metabolism), kidney and liver function markers, reactive oxidative species, and potential safety-related biomarkers .

3. The exploratory objective was to characterize the systems-level effects of NAD+ augmentation in humans through comprehensive multi-omic profiling of peripheral blood samples. High-throughput plasma metabolomics characterized the metabolic fate of administered NAD+ and identified downstream metabolic reprogramming. Proteomic profiling using high-throughput targeted discovery proteomics evaluated changes in circulating proteins relevant to inflammation, metabolism, and cellular stress responses. This unbiased discovery approach was designed to also identify novel candidate biomarkers of NAD+ response and potentially identify subpopulations most likely to benefit from intervention.

Conditions

Health Adult Subjects; Healthy Participants

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

Treatment arm

LNAD+ (50%)/PEG (50%) treatment total 500 mg

Group Type: EXPERIMENTAL

LathMized TM NAD+ (LNAD+)

Intervention Type: DIETARY_SUPPLEMENT

NAD+ 500 mg

Control arm

PEG 500 mg

Group Type: PLACEBO_COMPARATOR

Control (placebo)

Intervention Type: OTHER

PEG (100% of mass)

Interventions

LathMized TM NAD+ (LNAD+)

NAD+ 500 mg

Intervention Type: DIETARY_SUPPLEMENT

Control (placebo)

PEG (100% of mass)

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Participants able to consent for themselves;
• Able to commit to the study protocol, including a 7-day washout of potentially confounding substances via restriction of supplement intake;
• Tolerance for repeated venous blood draws, supplement administration, and assessment schedule, tolerance for wrist-worn wearable devices well (i.e., consistent use during the day as well as at night for the duration of the study).

Exclusion Criteria

• Body Mass Index (BMI) > 35 kg/m2;
• Current chronic or acute infectious diseases (e.g., hepatitis, influenza, HIV, Lyme; COVID-19 within the past two months);
• Recent SARS-CoV-2 vaccine administration (within two weeks);
• Current use of NAD+ supplements and precursors;
• Use of systemic anti-inflammatory medications (excluding NSAIDs and acetaminophen), immunosuppressants;
• Current cancer or hematologic conditions and/or cancer treatment (radiation, chemotherapy);
• Type I juvenile or Type 2 diabetes mellitus;
• Autoimmune disorders (multiple sclerosis, lupus, rheumatoid arthritis, psoriasis);
• Inflammatory bowel disease (ulcerative colitis, Crohn's disease);
• Current pregnancy;
• Current substance abuse, including alcohol, but excluding nicotine and prescription medications (e.g., physician-prescribed stimulants, opiates);
• Members of the same household.

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

ISB Analytica, LLC

UNKNOWN

Sponsor Role: collaborator

BioNADrx Holdings, Inc. Bryleos

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

ISB Bioanalytica, Inc.

Seattle, Washington, United States

Countries

United States

Other Identifiers

1320748

Identifier Type: -

Identifier Source: org_study_id